Searchable abstracts of presentations at key conferences in endocrinology

ea0089c41 | Clinical – Surgery/Applied Pathology | NANETS2022

SSTR-2 Expression in Solid Tumors: An Immunohistochemistry Analysis

Chauhan Aman , Arnold Susanne , Bocklage Therese , Yan Donglin , Li Ning , Anthony Lowell , Allison Derek

Background: Somatostatin receptor (SSTR) expression has been characterized in well-differentiated neuroendocrine tumors (NET). However, the understanding of receptor expression in various non-neuroendocrine solid tumors is limited. This study was performed to evaluate SSTR-2 in various cancers to provide a rational basis for SSTR-2 targeted anti-cancer therapies.Methods: Formalin-fixed paraffin, paraffin-embedded tissue was obtained from pathology archiv...

ea0098c38 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

Are there any clinical factors associated with PRRT-refractoriness in NET patients?

Gupta Garima , Yadav Rina , Yan Donglin , Anthony Lowell , Ramirez Robert , Chauhan Aman

Background: Peptide receptor radionuclide therapy (PRRT) with Lutetium-177 DOTATATE (LUTATHERA) is an effective treatment option for somatostatin receptor (SSTR) positive metastatic gastroenteropancreatic neuroendocrine tumors (NETs) and has also demonstrated antitumor activity in SSTR positive NETs from other primary sites. While the median progression free survival (mPFS) is around 29 months, there is a subset of patients who are refractory to PRRT and demonstrate progressio...

ea0089c13 | Clinical – Chemo/SSA/Biologics | NANETS2022

Serum Serotonin Compared to Plasma 5-HIAA and Chromogranin A as Biomarkers of Response to Hepatic Artery Bland Embolization

Blanford Cole , Yan Donglin , Li Ning , Woodworth Alison , Gabriel Gaby , Khouli Riham El , Chauhan Aman , Anthony Lowell

Background: Chromogranin A (CGA) and 5-HIAA are meaningful biomarkers in managing neuroendocrine tumors (NETs). CGA, though nonspecific, can reflect disease bulk and typically decreases after debulking surgery. 5-HIAA is specific to NETs though its measurement may require a special diet, a 24-hour urine collection, or specialized blood collection tubes; but usually decreases after debulking procedures. Serotonin, though useful in diagnosing NETs, is not followed as a biomarker...

ea0098c15 | Clinical – Chemo/SSA/Biologics | NANETS2023

Phase II study of frontline maintenance rucaparib in combination with nivolumab in extensive stage small cell lung cancer

Chauhan Aman , Kolesar Jill , Yan Donglin , Hao Zhonglin , McGarry Ronald , Villano John , Zinner Ralph , Maskey Ashish , Miller Jordan , Mullett Timothy , Khurana Aman , Zhou Xitong , Gupta Garima , Flora Daniel , Darnell Colleen , O'Neil Richard , Kunos Charles , Anthony Lowell , Arnold Susanne

Background: Immune checkpoint inhibitor (ICI) maintenance therapy is the standard of care for frontline management of extensive-stage small cell lung cancer (ES SCLC). However, the overall survival benefit of the addition of ICI maintenance to frontline ES SCLC treatment is modest and further improvement is needed. We hypothesized that the addition of poly (ADP-ribose) polymerase inhibition to ICI maintenance therapy for patients with platinum-sensitive ES SCLC could improve t...

ea0046p11 | (1) | UKINETS2016

Assessing treatment benefit of telotristat etiprate in patients with carcinoid syndrome: Patient exit interviews

Anthony Lowell , Horsch Dieter , Ervin Claire , Kulke Matthew H. , Pavel Marianne , Bergsland Emily , Caplin Martyn , Oberg Kjell , Warner Richard , Kunz Pamela , Metz David C. , Pasieka Janice , Pavlakis Nick , DiBenedetti Dana , Haydysch Emily , Yang Qi Melissa , Jackson Shanna , Arnold Karie , Law Linda , Lapuerta Pablo

Background: Telotristat etiprate (TE), an oral tryptophan hydroxylase inhibitor, is intended to treat carcinoid syndrome (CS) by reducing serotonin production. TE was evaluated in TELESTAR, a phase 3 study; the primary endpoint showed significant reductions in bowel movement (BM) frequency for 2 TE dosages + standard of care (SOC) vs. SOC. TELESTAR patients had CS inadequately controlled on somatostatin analog therapy with ≥4 BMs per day. They were interviewed about base...

ea0098c27 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

ETCTN 10388: A first in human Phase I Trial of Triapine and Lutetium Lu 177 DOTATATE in Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Chauhan Aman , Arnold Susanne , Kolesar Jill , Carson William , Weiss Heidi , Yan Donglin , El Khouli Riham , Khurana Aman , Beumer Jan , Soares Heloisa , Mulcahy Mary , Halfdanarson Thorvardur , Li Daneng , Jacene Heather , Ivy Percy , Kohn Elise , Wright John , Rubinstein Larry , Kunos Charles , Anthony Lowell , Konda Bhavana

Background: Radiation is a potent inducer of DNA double-strand breaks, and ribonucleotide reductase (RNR) is the rate-limiting enzyme in the synthesis and repair of DNA, making RNR-targeted therapy a rationale therapeutic strategy for radiosensitization. ETCTN 10388 (NCT04234568) evaluated safety and efficacy of the combination of lutetium 177 DOTATATE, a beta-emitting radionuclide in combination with triapine, a ribonucleotide reductase (RNR) inhibitor. <p class="abstext"...

ea0098c28 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

ETCTN 10450: A phase I trial of peposertib and lutetium 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Chauhan Aman , Kolesar Jill , Yan Donglin , Li Daneng , Khurana Aman , Edgar Carson William , Arnold Susanne M. , Gore Steven , Rubinstein Larry , Kohn Elise C. , Percy Ivy S. , Xiao Ying , Dewaraja Yuni , Soares Heloisa P. , Hendrik Beumer Jan , Konda Bhavana , Sukrithan Vineeth , Brian Anthony Lowell

Background: Radiolabeled somatostatin analogs provide a means of delivering targeted radiation with a high therapeutic index to NETs that express somatostatin receptors (SSTRs). We hypothesize that the addition of an effective radiation sensitizer could help improve the antitumor activity of Lutathera. Radiation is a potent inducer of DNA damage. The primary repair mechanism of radiation-induced double-stranded breaks (DSBs) is the nonhomologous end-joining (NHEJ) pathway, in ...